Literature DB >> 8724976

Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide.

C D Breder1, C B Saper.   

Abstract

Cyclooxygenase (COX) is an enzyme involved in the biosynthesis of prostaglandins and is one of the principle targets of non-steroidal anti-inflammatory drugs. Two isoforms of this enzyme are known to exist in the brain; one of these (type 1 COX or COX1) is constitutively expressed, whereas the other form of the enzyme, which is inducible, has been called type 2 COX (COX2). We have used systemic administration of bacterial lipopolysaccharide (LPS) as a model of the acute phase response to study the expression of COX2 in the murine CNS. We observed COX2 expression in neurons of several regions of the normal murine telencephalon. Robust expression of COX2 mRNA was induced in perivascular cells between 45 min and 6 h after LPS injection. The role of prostaglandins produced by these perivascular cells in the cerebral components of the acute phase response remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724976     DOI: 10.1016/0006-8993(95)01474-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

1.  COX-2: a link between airway inflammation and disordered chloride secretion in cystic fibrosis?

Authors:  A Clayton; A J Knox
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

Review 2.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

3.  Coexpression of microsomal-type prostaglandin E synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever.

Authors:  K Yamagata; K Matsumura; W Inoue; T Shiraki; K Suzuki; S Yasuda; H Sugiura; C Cao; Y Watanabe; S Kobayashi
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 4.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy.

Authors:  J A Mitchell; T D Warner
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.

Authors:  Hao Huang; Qian Hong; Hong-Ling Tan; Cheng-Rong Xiao; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

7.  Prevention of lipopolysaccharide-induced intussusception in mice by the COX2 inhibitor rofecoxib.

Authors:  Mahmoud Badriyyah; Haggi Mazeh; Stefan Brocke; Venera Osmanova; Herbert R Freund; Menachem Hanani
Journal:  Pediatr Surg Int       Date:  2007-11-06       Impact factor: 1.827

8.  Systemic administration of lipopolysaccharide induces cyclooxygenase-2 immunoreactivity in endothelium and increases microglia in the mouse hippocampus.

Authors:  Dae Won Chung; Ki-Yeon Yoo; In Koo Hwang; Dae Won Kim; Jin Young Chung; Choong Hyun Lee; Jung Hoon Choi; Soo Young Choi; Hwa Young Youn; In Se Lee; Moo-Ho Won
Journal:  Cell Mol Neurobiol       Date:  2009-11-12       Impact factor: 5.046

9.  Ventromedial preoptic prostaglandin E2 activates fever-producing autonomic pathways.

Authors:  T E Scammell; J K Elmquist; J D Griffin; C B Saper
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

10.  Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.

Authors:  S G Temel; Z Kahveci
Journal:  J Mol Histol       Date:  2010-01-06       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.